Translate
Arrivent Biopharma, Inc.
About
27.00USD-0.22 -0.81%
Closed • Updated at 13:42 GMT+00:00Market Cap$1.26B
Volume475.4K
Beta0.88
RSI42.54
Arrivent Biopharma, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 11 2026
ArriVent BioPharma Reports First Quarter 2026 Financial Results
May 7 2026
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
Mar 17 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Mar 5 2026
ArriVent BioPharma Reports Full Year 2025 Financial Results
Dec 22 2025
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
Recent Videos
ArriVent’s Next Big Breakthrough? 🚀 #shorts #americanews #trendingnews #usanews
May 16, 2026
Arrivent Biopharma Inc. 2026 quarterly report
May 12, 2026
Comprar acciones de ArriVent Biopharma Inc: guía rápida (AVBP)
Mar 21, 2026
ArriVent BioPharma's Governance: Here's What I Noticed
Jun 26, 2025